跳至主要内容
临床试验/IRCT20140221016666N4
IRCT20140221016666N4招募中3 期

Efficacy and Safety of nano-curcumin on the clinical condition of patients with hemorrhagic stroke: A randomized, assessor-blind, parallel-group pilot study

Mazandaran University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 80 years(—)
性别
All

入选标准

  • Age 18-80 years,
  • Diagnosis of ICH by brain CT scan,
  • NIHSS> 4 and MRS <2 presymptomatic,
  • bleeding in the putamen area,
  • Glasgow criterion (GCS greater than 8)
  • informed consent of the patient or first-degree relatives.

排除标准

  • Allergy to turmeric,
  • liver disease with liver enzyme more than three times of normal range
  • kidney disease or creatine more than 2,
  • candidate for surgery and hematoma evacuation,
  • secondary ICH for anticoagulant use and tumor and aneurysm and AVM,
  • infratentorial hemorrhage,
  • platelet count / 75,000 mm3 <,
  • INR <1.4,
  • fever at initial visit,
  • other inflammatory diseases including pneumonia, hematology, rheumatology, urinary tract infection on admission.
  • Immune suppressant drugs,]
  • absorption syndromes,
  • history of diabetes, smoking, alcohol and drug use

研究者

相似试验